Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD

2024/11/18 by Mia Jensen, Steffen Flindt Nielsen, Steffen Thiel +6 · 1 voice
Immunology and Microbiology · Medicine · #Complement system in diseases #Diabetes Treatment and Management #Erythropoietin and Anemia Treatment

paper · pdf · doi:10.1016/j.ekir.2024.11.014

openalex created_date 2024/11/18 · openalex publication_date 2024/11/18 · openalex updated_date 2026/07/23

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT-2i’s) improve kidney and cardiovascular outcomes in patients with diabetic nephropathy beyond antihypertensive and glucose-lowering effects.1 In patients with albuminuria, complement precursors are aberrantly filtered and subsequently activated in tubular fluid.2,3 Patients with diabetes and albuminuria are prone to complement binding to metabolically stressed and hyperactive SGLT-2–expressing tubular cells. Pattern-recognition molecules in the lectin pathway of complement, including MBL, collectin kidney 1 (CL-K1), and collectin liver 1 are associated with diabetic nephropathy.

Discussions

• Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor #Empagliflozin Shows #Reduced Intrarenal #Complement Activation in Patients With #Diabetes and #CKD doi.org/10.1016/j.ek... #KIRResearchLetter [bsky, 3 points, 0 comments]

Related

• SGLT2 inhibitors in CKD: are they really effective in all patients?
• The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
• Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q
• Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications
• SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits